[Form 4] Castle Biosciences, Inc. Insider Trading Activity
Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences (CSTL), reported the sale of 12,677 shares of the company's common stock in a transaction executed at a weighted-average price of $22.019 per share. The reported sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and, after the transaction, the reporting person beneficially owned 141,116 shares. The filing discloses that the sale occurred in multiple trades at prices ranging from $22.000 to $22.145 and that the reporting person will provide detailed trade-level information on request.
Kristen M. Oelschlager, Chief Operating Officer di Castle Biosciences (CSTL), ha venduto 12.677 azioni dell'ordinario della societ脿 in un'operazione eseguita a un prezzo medio ponderato di 22,019 $ per azione. La vendita 猫 stata effettuata ai sensi di un piano di negoziazione ai sensi della Rule 10b5-1 adottato dalla persona che ha presentato la segnalazione e, dopo la transazione, la stessa deteneva beneficiariamente 141.116 azioni. La comunicazione specifica che la vendita 猫 avvenuta in pi霉 operazioni a prezzi compresi tra 22,000 $ e 22,145 $ e che la persona che ha presentato la segnalazione fornir脿 informazioni dettagliate a livello di singole operazioni su richiesta.
Kristen M. Oelschlager, directora de operaciones de Castle Biosciences (CSTL), vendi贸 12.677 acciones del capital social de la compa帽铆a en una transacci贸n ejecutada a un precio medio ponderado de 22,019 $ por acci贸n. La venta se realiz贸 conforme a un plan de negociaci贸n bajo la Regla 10b5-1 adoptado por la persona informante y, tras la transacci贸n, dicha persona pose铆a de forma beneficiaria 141.116 acciones. La presentaci贸n revela que la venta se efectu贸 en m煤ltiples operaciones a precios que oscilaron entre 22,000 $ y 22,145 $ y que la persona informante facilitar谩 informaci贸n detallada por operaci贸n si se le solicita.
Castle Biosciences(CSTL)鞚� 斓滉碃鞖挫榿毂呾瀯鞛�(Chief Operating Officer)鞚� Kristen M. Oelschlager電� 須岇偓 氤错喌欤� 12,677欤茧ゼ 欤茧嫻 臧�欷戫弶攴� 臧�瓴� 22.019雼煬鞐� 毵る弰頄堨姷雼堧嫟. 頃措嫻 毵る弰電� 氤搓碃鞚胳澊 毂勴儩頃� Rule 10b5-1 瓯半灅瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞙茧┌, 瓯半灅 頉� 氤搓碃鞚胳潃 鞁れ鞝侅溂搿� 141,116欤茧ゼ 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖靹滊電� 毵る弰臧� 鞐煬 瓯挫潣 瓯半灅搿� 鞚措（鞏挫鞙茧┌ 瓯半灅 臧�瓴╇寑臧� 22.000雼煬鞐愳劀 22.145雼煬 靷澊鞓�鞚岇潉 氚濏瀳瓿�, 氤搓碃鞚胳潃 鞖旍箔 鞁� 臧滊硠 瓯半灅氤� 靸侅劯 鞝曤炒毳� 鞝滉车頃橁矤雼り碃 氇呾嫓頃橁碃 鞛堨姷雼堧嫟.
Kristen M. Oelschlager, directrice des op茅rations de Castle Biosciences (CSTL), a vendu 12 677 actions ordinaires de la soci茅t茅 dans une op茅ration ex茅cut茅e 脿 un prix moyen pond茅r茅 de 22,019 $ par action. La vente d茅clar茅e a 茅t茅 r茅alis茅e en vertu d'un plan de n茅gociation Rule 10b5-1 adopt茅 par la personne d茅clarante et, apr猫s la transaction, cette personne d茅tenait 脿 titre b茅n茅ficiaire 141 116 actions. Le d茅p么t indique que la vente a eu lieu en plusieurs transactions 脿 des prix compris entre 22,000 $ et 22,145 $ et que la personne d茅clarante fournira des informations d茅taill茅es au niveau de chaque transaction sur demande.
Kristen M. Oelschlager, Chief Operating Officer von Castle Biosciences (CSTL), ver盲u脽erte 12.677 Aktien der Stammaktien des Unternehmens in einer Transaktion zu einem gewichteten Durchschnittspreis von 22,019 $ pro Aktie. Der gemeldete Verkauf erfolgte gem盲脽 einem nach Rule 10b5-1 eingerichteten Handelsplan der berichtenden Person und nach der Transaktion hielt die berichtende Person wirtschaftlich 141.116 Aktien. Die Meldung f眉hrt aus, dass der Verkauf in mehreren Trades zu Preisen zwischen 22,000 $ und 22,145 $ stattfand und dass die berichtende Person auf Anfrage detaillierte transaktionsbezogene Angaben bereitstellen wird.
- Transaction executed under a Rule 10b5-1 plan, indicating trades were pre-scheduled and aiming to reduce potential timing concerns
- Weighted-average price and price range disclosed, and the reporting person offers to provide detailed trade-level information on request, enhancing transparency
- Reporting person retains a meaningful stake after the sale (141,116 shares), so control was not surrendered
- None.
Insights
TL;DR: Insider executed a planned sale under a 10b5-1 plan; transaction size appears routine relative to disclosed post-sale holdings.
The sale of 12,677 shares at a weighted-average $22.019 was executed under a pre-established Rule 10b5-1 plan, which typically indicates the trades were scheduled in advance to avoid timing concerns. The filing states the trades occurred across a narrow price range and that the reporting person retains 141,116 shares following the disposition. From a market-impact perspective, the disclosure promotes transparency but does not by itself indicate material change to company control or governance.
TL;DR: Use of a 10b5-1 plan and offer to provide trade details signals compliance and governance transparency.
Reporting the disposition and citing a Rule 10b5-1 plan aligns with governance best practices by documenting the affirmative defense for scheduled trades. The filer鈥檚 offer to supply trade-level data on request increases disclosure quality. The filing does not report any derivative transactions or other changes in indirect ownership, and it was signed by an attorney-in-fact, consistent with authorized reporting procedures.
Kristen M. Oelschlager, Chief Operating Officer di Castle Biosciences (CSTL), ha venduto 12.677 azioni dell'ordinario della societ脿 in un'operazione eseguita a un prezzo medio ponderato di 22,019 $ per azione. La vendita 猫 stata effettuata ai sensi di un piano di negoziazione ai sensi della Rule 10b5-1 adottato dalla persona che ha presentato la segnalazione e, dopo la transazione, la stessa deteneva beneficiariamente 141.116 azioni. La comunicazione specifica che la vendita 猫 avvenuta in pi霉 operazioni a prezzi compresi tra 22,000 $ e 22,145 $ e che la persona che ha presentato la segnalazione fornir脿 informazioni dettagliate a livello di singole operazioni su richiesta.
Kristen M. Oelschlager, directora de operaciones de Castle Biosciences (CSTL), vendi贸 12.677 acciones del capital social de la compa帽铆a en una transacci贸n ejecutada a un precio medio ponderado de 22,019 $ por acci贸n. La venta se realiz贸 conforme a un plan de negociaci贸n bajo la Regla 10b5-1 adoptado por la persona informante y, tras la transacci贸n, dicha persona pose铆a de forma beneficiaria 141.116 acciones. La presentaci贸n revela que la venta se efectu贸 en m煤ltiples operaciones a precios que oscilaron entre 22,000 $ y 22,145 $ y que la persona informante facilitar谩 informaci贸n detallada por operaci贸n si se le solicita.
Castle Biosciences(CSTL)鞚� 斓滉碃鞖挫榿毂呾瀯鞛�(Chief Operating Officer)鞚� Kristen M. Oelschlager電� 須岇偓 氤错喌欤� 12,677欤茧ゼ 欤茧嫻 臧�欷戫弶攴� 臧�瓴� 22.019雼煬鞐� 毵る弰頄堨姷雼堧嫟. 頃措嫻 毵る弰電� 氤搓碃鞚胳澊 毂勴儩頃� Rule 10b5-1 瓯半灅瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞙茧┌, 瓯半灅 頉� 氤搓碃鞚胳潃 鞁れ鞝侅溂搿� 141,116欤茧ゼ 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖靹滊電� 毵る弰臧� 鞐煬 瓯挫潣 瓯半灅搿� 鞚措（鞏挫鞙茧┌ 瓯半灅 臧�瓴╇寑臧� 22.000雼煬鞐愳劀 22.145雼煬 靷澊鞓�鞚岇潉 氚濏瀳瓿�, 氤搓碃鞚胳潃 鞖旍箔 鞁� 臧滊硠 瓯半灅氤� 靸侅劯 鞝曤炒毳� 鞝滉车頃橁矤雼り碃 氇呾嫓頃橁碃 鞛堨姷雼堧嫟.
Kristen M. Oelschlager, directrice des op茅rations de Castle Biosciences (CSTL), a vendu 12 677 actions ordinaires de la soci茅t茅 dans une op茅ration ex茅cut茅e 脿 un prix moyen pond茅r茅 de 22,019 $ par action. La vente d茅clar茅e a 茅t茅 r茅alis茅e en vertu d'un plan de n茅gociation Rule 10b5-1 adopt茅 par la personne d茅clarante et, apr猫s la transaction, cette personne d茅tenait 脿 titre b茅n茅ficiaire 141 116 actions. Le d茅p么t indique que la vente a eu lieu en plusieurs transactions 脿 des prix compris entre 22,000 $ et 22,145 $ et que la personne d茅clarante fournira des informations d茅taill茅es au niveau de chaque transaction sur demande.
Kristen M. Oelschlager, Chief Operating Officer von Castle Biosciences (CSTL), ver盲u脽erte 12.677 Aktien der Stammaktien des Unternehmens in einer Transaktion zu einem gewichteten Durchschnittspreis von 22,019 $ pro Aktie. Der gemeldete Verkauf erfolgte gem盲脽 einem nach Rule 10b5-1 eingerichteten Handelsplan der berichtenden Person und nach der Transaktion hielt die berichtende Person wirtschaftlich 141.116 Aktien. Die Meldung f眉hrt aus, dass der Verkauf in mehreren Trades zu Preisen zwischen 22,000 $ und 22,145 $ stattfand und dass die berichtende Person auf Anfrage detaillierte transaktionsbezogene Angaben bereitstellen wird.
FAQ
What did Castle Biosciences (CSTL) insider Kristen Oelschlager report on Form 4?
Was the insider sale part of a trading plan for CSTL?
How many Castle Biosciences shares does the reporting person own after the sale?
What price range did the CSTL insider trades occur at?
Were any derivative securities or option exercises reported by the insider?
